Upcoming Events

Practical Insights in and Translational Aspects of Novel Immune Therapies in Multiple Myeloma

Practical Insights in and Translational Aspects of Novel Immune Therapies in Multiple Myeloma

October 11, 2024 - Basel, Switzerland

Are you a hematologist or oncologist treating patients with multiple myeloma?
If so, this workshop is for you!

This high-impact educational program, held in conjunction with the DGHO Annual Meeting, seeks to bridge the knowledge gap between CAR T administering centers and smaller community centers where the vast majority of oncology patients are treated, and raise awareness of novel immune based strategies including antibody drug conjugates, bispecific T cell engages, and CAR T therapies among healthcare professionals.

 Preliminary Agenda

The treatment of multiple myeloma has dramatically evolved in recent years with immune-based strategies resulting in a very high impact in the relapsed refractory setting. Several targets are being evaluated, but B cell maturation antigen (BCMA) has proven to result in high response rates with excellent duration of responses in a very heavily pretreated patient population. Given the plethora of different drug products in this space, including antibody-drug conjugates, T cell engagers and CAR T cells, this is a busy landscape and requires specific education around patient characteristics, treatment selection, and toxicity management to provide the best treatment options for our patients.

At the conclusion of this educational activity, you will be able to:
1. Understand the types of patients who should be considered for novel immune based strategies including bispecific T cell engagers and CAR T cell therapy.
2. Understand the differences between TCEs, antibody drug conjugates, and CAR T cell process and data for appropriate care of the patient prior to consideration for these therapies.
3. Understand toxicities and their management post-novel immune strategies.

WebIMarS Series: Relapsed Refractory MM

WebIMarS Series: Relapsed Refractory MM

October 20, 2024 - Webinar

IMS is proud to announce the new webIMarS series, where with the leadership of local hematology groups, we will co-host a series of 90-minute webinars on Relapsed Refractory Multiple Myeloma around the globe.

Join our colleagues with the Mumbai Hematology Group, on Sunday, October 20 beginning at 11:30 am India Standard Time.

 

Program

Educational Workshop Johannesburg, South Africa

Educational Workshop Johannesburg, South Africa

February 28 - March 1, 2025 - Radisson Hotel & Convention Centre, Johannesburg, South Africa

Join us for a dynamic educational workshop on the diagnosis, treatment, and monitoring of plasma cell malignancies, including current practices and opportunities for improvement. This workshop will include lectures plus roundtable discussions around hot and controversial topics, featuring point-counterpoint conversations between invited speakers and local hematologists based on both challenging questions and clinical cases.

6th Immune Effector Cell Therapies in Multiple Myeloma Workshop

6th Immune Effector Cell Therapies in Multiple Myeloma Workshop

March 28 - 29, 2025 - Boston Marriott Long Wharf, Boston, MA

IMS is pleased to announce that the 6th Annual Immune Effector Cell Therapies in Multiple Myeloma Workshop will take place from March 28-29, 2025 in Boston, MA.

More details will be available soon! 

Educational Workshop Marrakech, Morocco

Educational Workshop Marrakech, Morocco

April 25 - 26, 2025 - Radisson Blu Hotel, Marrakech Carre Eden

Join us for a dynamic educational workshop on the diagnosis, treatment, and monitoring of plasma cell malignancies, including current practices and opportunities for improvement. This workshop will include lectures plus roundtable discussions around hot and controversial topics, featuring point-counterpoint conversations between invited speakers and local hematologists based on both challenging questions and clinical cases.

 

Translational Research Award

Career Development Award

IMS Young Investigator Award

COMING SOON – ARTEMIS

Meet the recipients of the IMS Translational Research Award!

Meet the recipients of the IMS Career Development Award!

About Our Publications

As a response to the current pandemic, the International Myeloma Society Executive Committee has developed the following Recommendations for the Management of Myeloma Patients During the COVID-19 Pandemic. These recommendations include directions for caring for newly diagnosed, elderly, relapsed/refractory and clinical trial patients. Please follow as appropriate for your practice and patient needs. The International Myeloma Society remains committed to keeping patients and physicians safe while providing care and treatment under these extraordinary circumstances.

See All Publications

Recommendations for the Management of Myeloma Patients During the COVID-19 Pandemic

As a response to the current pandemic, the International Myeloma Society Executive Committee has developed the following Recommendations for the Management of Myeloma Patients During the COVID-19 Pandemic. These recommendations include directions for caring for newly diagnosed, elderly, relapsed/refractory and clinical trial patients. Please follow as appropriate for your practice and patient needs. The International Myeloma Society remains committed to keeping patients and physicians safe while providing care and treatment under these extraordinary circumstances.

Why Become a Member

The International Myeloma Society is a professional, scientific, and medical society established to bring together clinical and experimental scientists involved in the study of myeloma. The purpose of this society is to promote research, education, clinical studies (including diagnosis and treatment), workshops, conferences, and symposia on all aspects of multiple myeloma worldwide.

The IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners.

Stay updated on our Events